French regulatory reform talks could have wider European implications
This article was originally published in SRA
Executive Summary
Some idea of the changes in store for the French regulatory system is beginning to emerge from a wide-ranging stakeholder consultation being held in the wake of the scandal involving the diabetes/slimming drug Mediator (benfluorex)1.